Abstract
Objective
To determine if removing an ovary for ovarian tissue cryopreservation (OTC) increased
rates of primary ovarian insufficiency (POI) in girls undergoing bone marrow transplantation
(BMT). Institutional review board approval was obtained from all 3 clinical sites.
Design
Multicenter retrospective cohort study
Setting
Academic children's hospitals
Patients
Females aged 2-21 who underwent BMT with or without OTC from 2010 to 2017.
Interventions
None
Main Outcome Measures
Rates of POI in girls who underwent OTC vs those who underwent BMT alone as determined
by serum markers, presence of menses, or clinical diagnosis.
Results
A total of 142 patients were identified, 43 who had OTC and 99 with BMT alone. The
rate of POI in girls undergoing OTC was 65% vs 41.8% in those who underwent BMT alone
(P = .26).
Conclusions
Although this study was not powered to detect a lack of difference, it is reassuring
that there does not seem to be a clinically significant increase in POI in patients
undergoing OTC.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Fertility preservation for young patients with cancer: who is at risk and what can be offered?.Lancet Oncol. 2005; 6: 209-218
- How does bone marrow transplantation affect ovarian function and fertility?.Curr Opin Obstet Gynecol. 2012; 24: 164-171
- Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the Pediatric initiative Network risk stratification system.J Adolesc Young Adult Oncol. 2020; 9: 662-666
- Fertility preservation in young females with hematological malignancies.Acta Haematol. 2014; 132: 400-413
- Clinician provision of oncofertility support in cancer patients of a reproductive age: a systematic review.Psychooncology. 2018; 27: 748
- Fertility preservation in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol. 2018; 36: 1994
- Cryopreservation of mature and immature oocytes.Clin Obstet Gynecol. 2010; 53: 763
- Cryopreservation and transplantation of ovarian tissue.Clin Obstet Gynecol. 2010; 53: 787
- Fertility preservation: the rationale for cryopreservation of the whole ovary.Semin Reprod Med. 2009; 27: 465
- Current success and efficiency of autologous ovarian transplantation: a meta-analysis.Reprod Sci. 2017; 24: 1111
- Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.Fertil Steril. 2019; 112: 1022-1033
- Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?.J Assist Reprod Genet. 2020; 37: 1323-1326
- Preliminary experience of ovarian tissue cryopreservation procedure: alternatives, perspectives, and feasibility.Reprod Biomed Online. 2003; 7: 572-579
- Dolmans MM: Techniques for ovarian tissue transplantation and results.Minerva Ginecol. 2018; 70: 424-431
- Pediatric reference intervals for FSH, LH, estradiol, T3, free T3, cortisol, and growth hormone on the DPC IMMULITE 1000.Clin Chim Acta. 2005; 355: 205-210
- Anti-Mullerian hormone: a new marker for ovarian function.Reproduction. 2006; 131: 1-9
- Primary ovarian insufficiency in adolescents and young women.Obstet Gynecol. 2014; 123: 193-197
- Primary ovarian insufficiency.N Engl J Med. 2020; (360): 606-614
- Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease.Oncologist. 2007; 12: 1437-1442
- The fertility potential of women with a single ovary.Hum Reprod Update. 1999; 5: 546
- Is unilateral oophorectomy associated with age at menopause? A population study (the HUNT2 survey).Hum Reprod. 2014; 29: 835-841
- Anti-Müllerian hormone and inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.Bone Marrow Transplant. 2020; 55: 1985-1995
- Recommendations for fertility preservation in patients with lymphomas.J Assist Repro Genet. 2012; 29: 473-477
- Casper RF: Ovarian cortex cryopreservation in pediatric and adolescent medicine.J Pediatr Adolesc Gynecol. 2000; 13: 95
- Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center.Acta Obstet Gynecol Scand. 2019; 98: 630-637
- The Committee on Bioethics, Section on Hematology/Oncology, and Section on Surgery. Preservation of fertility in pediatric and adolescent patients with cancer.Pediatrics. 2008; 121: e1461-e1469
- Practice Committee of American Society for Reproductive Medicine: Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.Fertil Steril. 2013; 100: 1214-1223
- Laparoscopic unilateral oophorectomy for ovarian tissue cryopreservation in children.J Pediatr Surg. 2019; 54: 543-549
Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, Version 4.0 Monrovia, CA. 2013. Available: www.survivorshipguidelines.org. Accessed October 23, 2018
- Early detection of ovarian dysfunction by anti-Mullerian hormone in adolescent and young adult-aged survivors of childhood cancer.J Adolesc Young Adult Oncol. 2018; https://doi.org/10.1089/jayao.2018.0080
- Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer.Hum Reprod. 2014; 29: 337-342
- Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study.Hum Reprod. 2008; 23: 2475-2483
- Anti-Mullerian hormone as a sensitive marker of ovarian function in young cancer survivors.Int J Endocrinol. 2013; 125080
- Anti-Mullerian hormone as a measure of reproductive function in female childhood cancer survivors.Fertil Steril. 2014; 101: 227-231
- Low anti-Mullerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy.J Pediatr Adolesc Gynecol. 2016; 29: 393-399
- Ovarian function after chemotherapy in young breast cancer survivors.Curr Oncol. 2017; 24: e494-e502
- Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation.Hum Reprod. 2005; 20: 3539-3546
Article info
Publication history
Published online: December 04, 2022
Accepted:
December 1,
2022
Received in revised form:
November 8,
2022
Received:
July 10,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
